Patents by Inventor Robert Kevin Perrone

Robert Kevin Perrone has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ORAL SOLID DOSAGE FORMULATION OF 1,1-DIMETHYLETHYL [(1S)-1-CARBAMOYL)PYRROLIDIN-1-YL]CARBONYL}-2,2-DIMETHYLPROPYL]CARBAMATE
    Publication number: 20150119317
    Abstract: The present invention is directed to an oral solid dosage formulation of Asunaprevir, 1,1-dimethylethyl[(1S)-1-{[(2S,4R)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({(1R,2S)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate, and to methods of using the formulation in the treatment and/or inhibition of the hepatitis C virus and infections caused thereby.
    Type: Application
    Filed: May 3, 2013
    Publication date: April 30, 2015
    Inventors: Rhye Hamey, Preetanshu Pandey, Dilbir S. Bindra, Chandra Vemavarapu, Robert Kevin Perrone
  • Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N-((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
    Patent number: 8338606
    Abstract: The present disclosure generally relates to crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N-((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide. The present disclosure also generally relates to a pharmaceutical composition comprising one or more of the crystalline forms, as well of methods of using the crystalline forms in the treatment of Hepatitis C virus (HCV) and methods for obtaining such crystalline forms.
    Type: Grant
    Filed: May 16, 2012
    Date of Patent: December 25, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Robert Kevin Perrone, Anne I. Song, Chenchi Wang, William Ying
  • CRYSTALLINE FORMS OF N-(TERT-BUTOXYCARBONYL)-3-METHYL-L-VALYL-(4R)-4-((7-CHLORO-4-METHOXY-1-ISOQUINOLINYL)OXY)-N-((1R,2S)-1-((CYCLOPROPYLSULFONYL)CARBAMOYL)-2-VINYLCYCLOPROPYL)-L-PROLINAMIDE
    Publication number: 20120230949
    Abstract: The present disclosure generally relates to crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N-((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide. The present disclosure also generally relates to a pharmaceutical composition comprising one or more of the crystalline forms, as well of methods of using the crystalline forms in the treatment of Hepatitis C virus (HCV) and methods for obtaining such crystalline forms.
    Type: Application
    Filed: May 16, 2012
    Publication date: September 13, 2012
    Inventors: Robert Kevin Perrone, Anne I. Song, Chenchi Wang, William Ying
  • Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
    Patent number: 8252821
    Abstract: Pharmaceutical capsule compositions containing the active compound (2R)-2-[[(4-chlorophenyl)sulfonyl][[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]-5,5,5-trifluoropentanamide, and polyethylene glycol (PEG), Vitamin E polyethylene glycol succinate, polyvinylpryrrolidone (PVP) or copovidone (PVP-Polyvinyl acetate), with or without citric acid, are provided.
    Type: Grant
    Filed: April 12, 2010
    Date of Patent: August 28, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Sachin Chandran, Rajesh Babulal Gandhi, Jaquan Kalani Levons, Robert Kevin Perrone, Christopher P. Price, Krishnaswamy Srinivas Raghavan, Ismat Ullah
  • Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
    Patent number: 8202996
    Abstract: The present disclosure generally relates to crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N-((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide. The present disclosure also generally relates to a pharmaceutical composition comprising one or more of the crystalline forms, as well of methods of using the crystalline forms in the treatment of Hepatitis C virus (HCV) and methods for obtaining such crystalline forms.
    Type: Grant
    Filed: December 8, 2008
    Date of Patent: June 19, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Robert Kevin Perrone, Anne I. Song, Chenchi Wang, William Ying
  • Bioavailable Capsule Compositions of Amorphous Alpha-(N-Sulfonamido)Acetamide Compound
    Publication number: 20100260837
    Abstract: Pharmaceutical capsule compositions containing the active compound (2R)-2-[[(4-chlorophenyl)sulfonyl][[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]-5,5,5-trifluoropentanamide, and polyethylene glycol (PEG), Vitamin E polyethylene glycol succinate, polyvinylpryrrolidone (PVP) or copovidone (PVP-Polyvinyl acetate), with or without citric acid, are provided.
    Type: Application
    Filed: April 12, 2010
    Publication date: October 14, 2010
    Inventors: Sachin Chandran, Rajesh Babulal Gandhi, Jaquan Kalani Levons, Robert Kevin Perrone, Christopher P. Price, Krishnaswamy Srinivas Raghavan, Ismat Ullah
  • CRYSTALLINE FORMS OF N-(TERT-BUTOXYCARBONYL)-3-METHYL-L-VALYL-(4R)-4-((7-CHLORO-4-METHOXY-1-ISOQUINOLINYL)OXY)-N-((1R,2S)-1-((CYCLOPROPYLSULFONYL)CARBAMOYL)-2-VINYLCYCLOPROPYL)-L-PROLINAMIDE
    Publication number: 20090202476
    Abstract: The present disclosure generally relates to crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N-((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide. The present disclosure also generally relates to a pharmaceutical composition comprising one or more of the crystalline forms, as well of methods of using the crystalline forms in the treatment of Hepatitis C virus (HCV) and methods for obtaining such crystalline forms.
    Type: Application
    Filed: December 8, 2008
    Publication date: August 13, 2009
    Inventors: Robert Kevin Perrone, Anne I. Song, Chenchi Wang, William Ying
  • Pharmaceutical compositions and methods of using taxane derivatives
    Publication number: 20040122081
    Abstract: The present invention relates to a novel intravenous formulation for a taxane chemotherapeutic agent. The agent is formulated as a two-container, i.e. vial system, with one container holding the therapeutic agent in a solvent with a buffer and the other container holding a co-solvent in a buffer. The contents of the two containers are mixed prior to administration.
    Type: Application
    Filed: November 7, 2003
    Publication date: June 24, 2004
    Inventors: Uday Shankar Gogate, Robert Kevin Perrone, Krishnaswamy Srinivas Raghavan
  • Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability
    Publication number: 20030220391
    Abstract: Disclosed are pharmaceutical compositions which comprise an orally-active taxane derivative and a pharmaceutically acceptable solubilizing agent, and which provide effective and consistent oral absorption of the taxane derivative.
    Type: Application
    Filed: December 19, 2002
    Publication date: November 27, 2003
    Inventors: Joseph Ballard Bogardus, Robert Kevin Perrone, Krishnaswamy Srinivas Raghavan, Sailesh Amilal Varia